Peptron, Inc. engages in the development of peptide-based medicines to treat chronic diseases. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, and puberty; SR-Octreotide (PT201) for the treatment of acromegaly; SR-Exenatide (PT302) to treat type 2 diabetes; and SR-Exenatide (PT320) for Parkinson's and Alzheimer's disease. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea.